The Rapid Deployment Vaccine Collaborative (Radvac) is a 501(c)(3) nonprofit organization formed to enable rapid production and deployment of safe and effective pathogen countermeasures (including low-cost vaccines; rapidly configurable antiviral therapies; broad-spectrum antiviral prophylactics; and the production capacity for each) in the earliest days of outbreaks. We create proof-of-principle demonstrations of early stage countermeasures, and freely share methods and protocols for decentralized production and deployment.

We believe that the foundation of effective countermeasures is maximal access in terms of both speed and geography, including and especially in low-resource areas. Two key ways we aim to fulfill the promise of maximal access is through self-production and self-administration of biosecurity tools.

Beginning in March 2020, in less than one month, we designed, produced, and self-administered the first of several progressive generations of nasal vaccines against SARS-CoV-2, and we shared all methods and protocols online in a series of white papers. We chose not to file patents or secured other intellectual property protections, and all information on our vaccine designs, production, self-administration, and testing has been freely shared on this website under open licenses (CC BY 4.0 and OCL-P v1.1) in partnership with the Creative Commons Open COVID Pledge.  To coordinate research efforts, we have established a collaborative network via our Researchers Map, and other outreach activities.